Obexelimab may represent ‘paradigm shift’ in IgG4-related disease

Patients with IgG4-related disease who received obexelimab demonstrated a 56% reduction in flare risk compared with those given placebo at 52 weeks, according to data presented at the EULAR 2026 Congress.“The most relevant unmet need in our clinical management of patients with IgG4-related disease is the chronic and relapsing nature of IgG4-related disease,” Emanuel Della Torre, MD,